Melinda Louie-Gao

Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial

Frank Griesinger, Giuseppe Curigliano, Michael Thomas et al. · Annals of Oncology · 2022 · 167 citations · Full text

Increased risk of brain metastases in ovarian cancer patients with BRCA mutations

Elena Ratner, Mohan Bala, Melinda Louie-Gao et al. · Gynecologic Oncology · 2019 · 51 citations

Cancer Risk, Brain Metastases, Medicine +7

Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis

Andreas Reiter, Jason Gotlib, Iván Álvarez‐Twöse et al. · Leukemia · 2022 · 48 citations · Full text

A phase 1/2 study of BLU-945 in patients with common activating <i>EGFR</i>-mutant non–small cell lung cancer (NSCLC): SYMPHONY trial in progress.

Elaine Shum, Yasir Y. Elamin, Zofia Piotrowska et al. · Journal of Clinical Oncology · 2022 · 15 citations

Pathology, Pharmacotherapy, Tumor Biology +20

AcceleRET Lung: A phase III study of first-line pralsetinib in patients (pts) with RET-fusion+ advanced/metastatic non-small cell lung cancer (NSCLC).

Benjamin Besse, Enriqueta Felip, Corinne Clifford et al. · Journal of Clinical Oncology · 2020 · 14 citations

Immunology, Pathology, Ret-fusion+ Nsclc +16